<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002191</url>
  </required_header>
  <id_info>
    <org_study_id>274A</org_study_id>
    <secondary_id>SK 62979/029</secondary_id>
    <secondary_id>GHBA 659</secondary_id>
    <nct_id>NCT00002191</nct_id>
  </id_info>
  <brief_title>A Double-Blind, Placebo-Controlled Trial of Albendazole in HIV-Positive Patients With Intestinal Microsporidiosis</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Trial of Albendazole in HIV-Positive Patients With Intestinal Microsporidiosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SmithKline Beecham</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the efficacy (stool frequency) and safety (adverse experiences) of albendazole,&#xD;
      administered for 28 days, compared to placebo and for 62 days in open-label fashion, in&#xD;
      treating intestinal microsporidiosis in HIV-positive patients. To assess the effect of&#xD;
      albendazole on stool volume, weight gain, microsporidial counts in small bowel biopsies, and&#xD;
      on the relationship between microsporidial counts in stool and stool frequency and volume. To&#xD;
      correlate microsporidial counts with the clinical course of microsporidiosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the double-blind portion of study, patients receive albendazole or placebo for 28 days; in&#xD;
      the open-label portion of study, patients receive albendazole for 62 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Protozoan Infections</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albendazole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  If coincident enteric pathogens that are not eradicable (i.e., Mycobacterium avium&#xD;
             complex) are detected, they should be treated appropriately and the patient must be on&#xD;
             a stable regimen of therapy for at least two weeks.&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Patients taking antidiarrheal medications must be on a stable regimen for at least&#xD;
             seven days prior to randomization.&#xD;
&#xD;
          -  Patients taking other concomitant medications, including antiretrovirals, must be on a&#xD;
             stable regimen for two weeks prior to randomization.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV positive status. Written documentation (for example, patient's chart) of HIV&#xD;
             diagnosis is acceptable in lieu of repeat testing. Confirmation by Western blot is not&#xD;
             necessary.&#xD;
&#xD;
          -  Biopsy-proven microsporidiosis of the fourth portion of the duodenum or proximal&#xD;
             jejunum within 90 days before randomization.&#xD;
&#xD;
          -  Average of &gt; 3 liquid bowel movements per day over 7 consecutive days immediately&#xD;
             prior to randomization, with an average volume &gt; 500 ml per day over three or more&#xD;
             consecutive days immediately prior to randomization, as documented by data collected&#xD;
             in a daily diary. NOTE:&#xD;
&#xD;
          -  Patients receiving antidiarrheal therapy must meet these criteria despite such&#xD;
             therapy.&#xD;
&#xD;
          -  History of an average of &gt; 3 liquid bowel movements per day for three additional weeks&#xD;
             immediately preceding the 7-day period described above (for a total of four weeks), as&#xD;
             documented in the patient's chart.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Grade 4 neutropenia.&#xD;
&#xD;
          -  Decompensated liver disease.&#xD;
&#xD;
          -  Positive toxin analysis for C. difficile.&#xD;
&#xD;
          -  Positive microscopic examination for Giardia lamblia, Entamoeba histolytica, and&#xD;
             Isospora belli.&#xD;
&#xD;
          -  Positive on culture for Shigella, Salmonella, Yersinia and Campylobacter.&#xD;
&#xD;
          -  Positive fluorescent antibody test for Cryptosporidium.&#xD;
&#xD;
          -  Evidence of CMV on small bowel biopsy, flexible sigmoidoscopic or colonoscopic&#xD;
             biopsies within 90 days of randomization.&#xD;
&#xD;
          -  Any other condition that, in the opinion of the investigator, makes the patient&#xD;
             unsuitable for study entry.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
        Hypersensitivity to albendazole.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Use of potential antiprotozoal drugs, e.g., mebendazole or metronidazole, within one&#xD;
             week prior to enrollment.&#xD;
&#xD;
          -  Receipt of albendazole during the one month prior to enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>San Francisco Gen Hosp / Div of GI</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Davies Med Ctr</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington Univ 5-403A</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deaconess Hosp / Harvard Med School / Infect Disease</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Univ</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hosp / Services and Research 1301</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 1997</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Placebos</keyword>
  <keyword>Protozoan Infections</keyword>
  <keyword>Intestinal Diseases</keyword>
  <keyword>Albendazole</keyword>
  <keyword>Microsporida</keyword>
  <keyword>Anthelmintics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Protozoan Infections</mesh_term>
    <mesh_term>Microsporidiosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albendazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

